Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a pioneering biotechnology company headquartered in the United States, focuses on advancing cell and gene therapies. Founded in 2014, Poseida has made significant strides in the industry, particularly in the development of innovative therapies for cancer and genetic diseases. The company is renowned for its proprietary technologies, including its non-viral gene editing platform and its unique approach to cell therapy, which enhances the precision and efficacy of treatments. Poseida's commitment to harnessing the power of the immune system positions it as a leader in the rapidly evolving field of immunotherapy. With a robust pipeline of clinical candidates and strategic partnerships, Poseida Therapeutics continues to solidify its market position, aiming to transform the landscape of therapeutic options available to patients worldwide.
DitchCarbon Score
How does Poseida Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Poseida Therapeutics, Inc.'s score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Poseida Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which may influence its climate commitments and emissions reporting. As of now, Poseida Therapeutics has not established any documented reduction targets or climate pledges. The absence of specific emissions data suggests that the company may be in the early stages of developing its sustainability strategy or reporting framework. Given its affiliation with Roche Holding AG, any potential climate initiatives or emissions data may be cascaded from this parent organisation. Roche has established various sustainability goals, which could indirectly impact Poseida's future commitments and performance in carbon emissions reduction. In summary, while Poseida Therapeutics, Inc. does not currently report specific emissions figures or reduction targets, its relationship with Roche may provide a pathway for future climate action and accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 320,860,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 209,660,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Poseida Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
